Research Topics
Genomes and Genes
Species | Anke Hilse Maitland-van der ZeeSummaryAffiliation: Utrecht University Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitorsAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Sorbonnelaan 16, P O BOX 80082, The Netherlands
Atherosclerosis 163:213-22. 2002..Determining the genotype will not deny therapy to a subject, but will help in deciding the therapy that will suit the patient best...- Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)Anke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
Acta Cardiol 61:327-31. 2006..corrected] The influence ofApoE polymorphism on the efficacy of statins in lowering plasma lipids and lipoproteins and improving angiographic parameters was assessed... - Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjectsAnke Hilse Maitland-van der Zee
Human Genetics Center, University of Texas Health Science Centre, Houston, TX 77030, USA
Am J Hypertens 18:1077-83. 2005..The aim of this study was to characterize interindividual variation in glucose and lipid responses to hydrochlorothiazide and to identify demographic, environmental, and genetic predictors associated with this variation... - A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazideAnke Hilse Maitland-van der Zee
Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
Pharmacogenet Genomics 15:287-93. 2005..To assess the influence of variations in multiple candidate genes on inter-individual variation in diastolic blood pressure (DBP) response to hydrochlorothiazide... 
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variantBas J M Peters
Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht University, Utrecht, The Netherlands
Pharmacogenet Genomics 18:631-6. 2008..Therefore, we assessed whether the effectiveness of statins in reducing the risk of MI was modified by the GNB3 C825T polymorphism...
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MIBas J M Peters
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
Atherosclerosis 217:458-64. 2011..In conclusion, ten SNPs were found to modify the effectiveness of statins in reducing the risk of MI in the UCP study. Five were also tested in the HVH study, but no interactions reached statistical significance...- Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarctionDiane B M A van Wieren-de Wijer
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands
J Hypertens 27:61-8. 2009..The Gly460Trp variant of the alpha-adducin gene has been associated with the salt-sensitive and diuretic responsive form of hypertension... - Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypesAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
Pharmacogenetics 13:219-23. 2003..18 (CI 1.01-10.03) in men. The apoE genotype is associated with discontinuation of statins. This suggests that subjects who are genetically prone to develop hypercholesterolemia show the highest risk of discontinuation of treatment... - Reasons for non-response in observational pharmacogenetic researchDiane B M A van Wieren-de Wijer
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, University of Utrecht, The Netherlands
Pharmacoepidemiol Drug Saf 18:665-71. 2009..We determined reasons for non-response and compared characteristics of non-responders and responders in a pharmacogenetic case-control study... - Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarctionBas J M Peters
Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
Pharmacogenomics 11:1065-76. 2010..Genetic variability within the SLCO1B1 and ABCB1 transporter genes has been associated with modification of statin effectiveness in cholesterol management... - Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8Ellen S Koster
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
Pharmacoepidemiol Drug Saf 19:991-9. 2010..ICS and SABA prescription occurs especially in those who were more likely to develop signs of asthma at age 8... - Uncontrolled asthma at age 8: the importance of parental perception towards medicationEllen S Koster
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
Pediatr Allergy Immunol 22:462-8. 2011..The aim of this study was to identify determinants of uncontrolled asthma at age 8 in children participating in the PIAMA birth cohort study... - Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in menAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht, The Netherlands
Pharmacogenetics 14:53-60. 2004..If other studies confirm that men with the DD genotype do not benefit from treatment with statins, screening for ACE genotype in men most likely will be a cost-effective strategy before initiating statin therapy... - Limited agreement between current and long-term asthma control in children: the PACMAN cohort studyEllen S Koster
Division of Pharmacoepidemiology and Clinical Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
Pediatr Allergy Immunol 22:776-83. 2011..To assess predictors of asthma control, we need firm outcome phenotypes. The aim of this study was to investigate the association between measurements of current and long-term asthma control... - The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT studyAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
Pharmacogenet Genomics 19:338-44. 2009..Statins have been shown to influence the expression of coagulation factors II, V, VII, XII and XIII... - The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotypeAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
Pharmacogenetics 12:647-53. 2002..The protective effect of statins on total mortality was not statistically significant, but did not seem to differ between subjects with different apoE genotypes... - Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based studySusanne J H Vijverberg
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
Pediatr Allergy Immunol 23:529-36. 2012..A high fraction of nitric oxide in exhaled breath (FeNO) has been suggested to be a marker of ongoing airway inflammation and poorly controlled disease in asthma. The usefulness of FeNO to monitor asthma control is still debated today... - Pharmacogenetics of response to statins: where do we stand?Anke Hilse Maitland-van der Zee
Human Genetics Center, Health Science Center at Houston, University of Texas, 1200 Hermann Pressler, Houston, TX 77030, USA
Curr Atheroscler Rep 7:204-8. 2005..Even though many studies have been performed, few results have been replicated. It is our contention that larger sample sizes and consideration of multiple genes are needed in the field of pharmacogenetics of statin response... - High agreement between parental reported inhaled corticosteroid use and pharmacy prescription dataEllen S Koster
Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
Pharmacoepidemiol Drug Saf 19:1199-203. 2010..This study was conducted to assess the validity of parental reported use of inhaled corticosteroids (ICS) in children... - Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance doseRianne M F van Schie
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
Pharmacogenomics 13:1917-23. 2012..To investigate whether the phenprocoumon and acenocoumarol maintenance doses are influenced by genetic variations in GATA-4, a transcription factor of CYP2C9... - Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort studyEllen S Koster
Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
Pharmacoepidemiol Drug Saf 20:1064-72. 2011..The aim of this study was to investigate factors associated with adherence in paediatric ICS users... - Asthma therapy during the first 8 years of life: a PIAMA cohort studyMira G P Zuidgeest
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
J Asthma 47:209-13. 2010..This study describes the formation of a longitudinal data set on asthma medication use and shows first results regarding the prevalence and incidence of medication use... - Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarctionAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, University of Utrecht, Utrecht, The Netherlands
J Renin Angiotensin Aldosterone Syst 12:208-14. 2011..This study investigated whether variation in the genes encoding for ACE, AGT and AGTR1 modifies the risk of myocardial infarction (MI) related to ACE inhibitors and AT II antagonists... - Asthma medication use in infancy: determinants related to prescription of drug therapyEllen S Koster
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht
Fam Pract 28:377-84. 2011..Little is known about factors that determine prescribing of asthma therapy in infancy... - Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarctionBas J M Peters
Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands
Pharmacogenet Genomics 20:766-74. 2010.... - Comparison of two methodologies to analyze exposure to statins in an observational study on effectivenessAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences (UIPS, Utrecht University, Sorbonnelaan 16, P.O. Box 80082, 3508 TB, The Netherlands
J Clin Epidemiol 57:237-42. 2004..59-1.39). CONCLUSION: Our results suggest that use of a time-dependent exposure definition is more accurate because estimates of effectiveness were more in agreement with results from randomized controlled trials of statin treatment... - Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original studyRianne M F van Schie
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
Pharmacogenomics 13:1239-45. 2012..The EU-PACT trial investigates the added value of pretreatment genotyping for use of warfarin, phenprocoumon and acenocoumarol... - Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatmentDiane B M A van Wieren-de Wijer
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, PO Box 80082, 3508 TB Utrecht, The Netherlands
Pharm World Sci 31:158-64. 2009..To describe the design, recruitment and baseline characteristics of participants in a community pharmacy based pharmacogenetic study of antihypertensive drug treatment... - Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic dataRianne M F van Schie
Study Coordinating Centre, Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands
Eur Heart J 32:1909-17. 2011..To provide physicians with tools to estimate the patient's individual dose, we aimed to develop algorithms for PHE and ACE... - Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: thAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
Pharmacogenet Genomics 18:651-6. 2008..High homocysteine blood concentrations predispose to coronary artery disease and statins influence homocysteine levels... - Methodological and statistical issues in pharmacogenomicsBas J M Peters
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
J Pharm Pharmacol 62:161-6. 2010..Finally, conventional as well as several innovative approaches to the analysis of large pharmacogenomic datasets are proposed that deal with the issues of multiple testing and systems biology in different ways... - Pharmacogenomic importance of pravastatinBas Peters
Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, The Netherlands
Pharmacogenomics 9:1207-10. 2008..This article reviews the most important studies conducted on the pharmacogenetics of pravastatin. Currently there is no evidence to advocate pharmacogenetic testing before initiating therapy... - Genetic determinants of response to statinsBas J M Peters
Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80082, 3508 TB, Utrecht, The Netherlands
Expert Rev Cardiovasc Ther 7:977-83. 2009..This article reviews the most important studies conducted on pharmacogenetics of statins. Currently, there is no evidence to advocate pharmacogenetic testing before initiating therapy... - Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costsTalitha I Verhoef
Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
Pharmacogenomics 13:1405-17. 2012..We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries... - Asthma symptoms in pediatric patients: differences throughout the seasonsEllen S Koster
Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
J Asthma 48:694-700. 2011..The aim of this study was to describe seasonal patterns of asthma symptoms and asthma medication use in a cohort of pediatric asthma medication users and to study determinants of seasonal childhood asthma... - Systems biology in pharmacogenomic research: the way to personalized prescribing?Ellen S Koster
Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80082, 3508 TB Utrecht, The Netherlands
Pharmacogenomics 10:971-81. 2009..Therefore, in the future, a multidisciplinary systems-based approach will be necessary to deal with the bulk of the biological data that is available and, ultimately, to reach the goal of personalized prescribing... - Pharmacogenetics and the pharmaceutical industryJan A M Raaijmakers
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, The Netherlands
Curr Pharm Des 16:238-44. 2010..In addition, collaborative efforts with academic partners are very much welcomed by the pharmaceutical industry and are expected to have a synergistic effect on progression in this field... - Pharmacogenetics of cardiovascular drug therapyBas J M Peters
Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
Clin Cases Miner Bone Metab 6:55-65. 2009..Therefore, new approaches are needed addressing issues and challenges such as the number of SNPs studied, study power, study design and application of new statistical methods in (pharmaco-)genetic analysis... - Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend studyMarjolein Geleedst-De Vooght
Lusse Pharmacy, Utrecht, The Netherlands
Drugs Aging 27:589-96. 2010..However, several studies have shown prescription rates of statins to be significantly lower in the elderly than in younger populations... - Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohortEllen S Koster
Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, 3508 TB Utrecht, The Netherlands
Pharmacogenomics 10:1351-61. 2009..To investigate the effects of genetic variation on treatment response to asthma medication in children and to identify (profiles of) SNPs that characterize response phenotypes... - Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam StudyAnke Hilse Maitland-van der Zee
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences (UIPS, Utrecht University, Utrecht, The Netherlands
Pharm World Sci 25:70-2. 2003..CONCLUSIONS: We conclude that the use of more than one nitrate prescription can be used as a marker for angina pectoris. This marker may be useful in epidemiological studies... - Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial designRianne M F van Schie
Utrecht University, Faculty of Science, Utrecht, The Netherlands
Pharmacogenomics 10:1687-95. 2009..The primary outcome measure is the percentage time in the therapeutic range for international normalized ratio. This report describes the design and protocol for the trial... - Workshop outcomes report: initiatives to establish a European Network of pharmacogenetics/genomics and progressAnke Hilse Maitland-van der Zee
Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
Eur J Pharm Sci 31:151-5. 2007 - Pharmacogenomic insights into treatment and management of statin-induced myopathyBas Jm Peters
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, University of Utrecht, 3508 TB Utrecht, The Netherlands
Genome Med 1:120. 2009..Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy... - Conference scene: initiatives on future biobanking in pharmacogenomicsSusanne Vijverberg
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, The Netherlands
Pharmacogenomics 10:1135-8. 2009..The European Association for Clinical Pharmacology and Therapeutics, GlaxoSmithKline and the Dutch Top Institute Pharma provided financial sponsorship... - A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivativesTalitha I Verhoef
Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands
Pharmacogenomics 11:989-1002. 2010..More reliable cost-effectiveness estimates need to become available before it is possible to recommend whether or not this strategy should be applied in clinical practice... - Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levelsAaron Isaacs
Genetic Epidemiology Unit, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
J Clin Endocrinol Metab 92:2680-7. 2007..The objectives of the current study were to characterize the effect of the hepatic lipase variant, and its interaction with the CETP variant, in terms of cholesterol levels, atherosclerosis, and risk of myocardial infarction (MI)... - Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) studyAnke Hilse Maitland-van der Zee
School of Public Health, University of Texas Health Science Center at Houston, 1200 Hermann Pressler, Houston TX, USA
Am Heart J 153:54-8. 2007.... - Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphismAnke-Hilse Maitland-van der Zee
Atherosclerosis 175:377-9. 2004 - Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?Tom Schalekamp
Thromb Haemost 100:175-6. 2008